NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Enveric Biosciences, Inc. ENVB
16 fiscal years on record · USD · FY2025 reported · SEC filings only
$-8.8M
Growth
—
Revenue, FY2025 · full 16-year series below
Revenue $M
Net income $M
FY2019 · Revenue 39.9 · Net income -2.4
Compound annual growth
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
—
Operating margin
Net margin
FY2019 · Operating -5.8% · Net -6.0%
ROE
FY2025 · ROE -304.0%
Each USD of equity lost 304 cents this year.
The 16-year record
16 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | · | · | · | · | · | · | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | · | · | · | · |
| Operating income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | 0.0 | 0.0 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.1 | · | · | · | · | −0.0 | −0.0 | · | · | · | · | · |
| Income tax $B | · | 0.0 | 0.0 | −0.0 | −0.0 | · | 0.0 | 0.0 | −0.0 | −0.0 | −0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | · | · | −0.0 | −0.0 | −0.0 | · | · | · | · | · | · | · | · | · | · | · |
| EPS, diluted $ | −36.24 | −228.48 | −121.29 | −13.00 | −2.07 | −1.19 | −0.46 | −20.47 | −0.75 | −0.21 | −0.07 | 0.00 | 0.00 | 0.00 | 0.00 | −0.01 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | −304.0 | −539.6 | −208.0 | −99.9 | −380.8 | −855.9 | · | −174.4 | −58.3 | −46.6 | −639.3 | · | · | · | · | · |
| Shares out B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 | 0.02 | 0.01 | 0.01 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 65 reconciliationsAUDITED
Reconciled in 16 of 19 fiscal years. 30 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2010